ML-193 N-(4-(N-(3,4-二甲基异恶唑-5-基)氨磺酰基)苯基)-6,8-二甲基-2-(吡啶-2-基)喹啉-4-甲酰胺
CAS 713121-80-3 MFCD13121803
化学结构图
SMILES:
别名和识别编码
| Chemical Name Translation | N-(4-(N-(3,4-二甲基异恶唑-5-基)氨磺酰基)苯基)-6,8-二甲基-2-(吡啶-2-基)喹啉-4-甲酰胺 |
|---|---|
| Chemical Name | ML-193 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Kotsikorou E, et, al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2013 Dec 31;52(52):9456-69.
- [3]. Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33(1):15-21.
- [4]. Hill JD, et, al. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol. 2018 Aug;175(16):3407-3421.
- [1]. Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30.
- [1]. Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30.
- [2]. Kotsikorou E, et, al. Identification of the GPR55
